Review of enterovirus 71 vaccines

Clinical Infectious Diseases

Volumn 60, Issue 5, 2015, Pages 797-803

  Chong, Pele ^a,b   Liu, Chia Chyi ^a   Chow, Yen Hung ^a,b   Chou, Ai Hsiang ^a   Klein, Michel ^c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c VaxiBio Inc   (Canada)

Author keywords

Enterovirus 71; Foot and mouth disease; Hand; Human enterovirus A (HEV A); Inactivated whole virion vaccine; Waning immunity

Indexed keywords

ENTEROVIRUS 71 VACCINE; INACTIVATED VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ASIA; CHINA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG POTENCY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; GENETIC RECOMBINATION; GENOTYPE; HUMAN; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGAPORE; TAIWAN; ANIMAL; ANTIGENIC VARIATION; BLOOD; CROSS PROTECTION; DISEASE MODEL; ENTEROVIRUS A; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; CLINICAL TRIALS, PHASE III AS TOPIC; CROSS PROTECTION; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; HAND, FOOT AND MOUTH DISEASE; HUMANS; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 84935425287     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu852     Document Type: Review

References (40)

1. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002; 26:91-107.
2. Solomon T, Lewthwarte P, Perera D, Cordosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect Dis 2010; 10:778-90.
3. Lee MS, Tseng FC, Chi CY, Wang JR, Chong P, Su IJ. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012; 6:e1737.
4. Lee MS, Chiang PS, Luo ST, et al. Incidence rates of enterovirus 71 infections in young children in Taiwan, 2008-2009. J Pediatr 2011; 29:1030-4.
5. Chang LY, Tsao KC, Hsia SH, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 2004; 291:222-7.
6. McMinn PC. Enterovirus vaccines for an emerging cause of brain-stem encephalitis. N Engl J Med 2014; 370:792-4.
7. Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 2009; 7:735-42.
8. Liang ZL, Mao Q, Gao F, Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 2013; 7:111-21.
9. Wang X, Peng W, Ren J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 2012; 19:424-9.
10. Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009; 15:798-801.
11. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 2009; 15:794-7.
12. Yamayoshi A, Fujii K, Koike S. Receptors for enterovirus 71. Emerg Microbes Infect 2014; 3:e53.
13. van der Sanden S, Koopmans M, Uslu G, van der Avvort H; Dutch Working Group for Clinical Virology. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J Clin Microbiol 2009; 47:2826-33.
14. Bessaud M, Razafindratsimandresy R, Nougairède A, et al. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS One 2014; 9:e90624.
15. Yip CCY, Lau SKP, Woo PCY, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J 2013; 6:19780.
16. Yu H, Chen W, Chang H, et al. Genetic analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A in central China in 2008. Virus Genes 2010; 41:1-4.
17. Kung YA, Hung CT, Liu YC, Shih SR. Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther 2014; 14:1455-64.
18. Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin 2011; 26:221-8.
19. Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010; 14:1076-81.
20. Mizuta K, Aoki Y, Matoba Y, et al. Molecular epidemiology of enterovirus 71 strains isolated from children in Yamagata, Japan, between 1990 and 2013. J Med Microbiol 2014; 63(pt10):1356-62.
21. Chia MY, Chiang PS, Chung WY, Luo ST, Lee MS. Epidemiology of enterovirus 71 infections in Taiwan. Pediatr Neonatol 2014; 55:243-9.
22. Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 2014; 14:308-18.
23. Huang SW, Cheng HL, Hsieh HY, et al. Mutations in the non-structural protein region contribute to intra-genotypic evolution of enterovirus 71. J Biomed Sci 2014; 21:33-47.
24. Chong P, Hsieh SY, Liu CC, et al. Production of EV71 vaccine candidates. Hum Vaccin Immunother 2012; 8:1-9.
25. Cheng A, Fung CP, Liu CC, et al. A phase 1, randomized, open-label study to evaluate the safety and immunogenicity of enterovirus 71 vaccine. Vaccine 2013; 31:2471-6.
26. Chou AH, Liu CC, Chang JY, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody responses against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013; 8: e79783.
27. Li JX, Mao QY, Liang ZL, Ji H, Zhu FC. Development of enterovirus 71 vaccines: from the lab bench to phase 3 clinical trials. Expert Rev Vaccines 2014; 13:609-18.
28. Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 38:2024-32.
29. Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014; 370:818-28.
30. Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370:829-37.
31. Mao Q, Cheng T, Zhu F, et al. The cross-neutralizing activity of enterovirus 71 subgenotype C4 vaccines in healthy Chinese infants and children. PLoS One 2013; 8:e79599.
32. Chen YJ, Meng FY, Mao QY, et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large scale phase 3 clinical trial. Hum Vaccin Immunother 2014; 10:1366-72.
33. Chong P, Guo MS, Lin FH, et al. Immunological and biochemical characterization of coxsackievirus A16 viral particles. PLoS One 2012; 7: e49973.
34. Cai Y, Ku Z, Liu Q, Leng Q, Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits a balanced protective immunity against both viruses. Vaccine 2014; 32:2406-12.
35. Wang YF, Yu CK. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 2014; 21:31-41.
36. Lin YW, Yu SL, Shao HY, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 2013; 8:e57591.
37. Fujii K, Nagata N, Sato Y, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA 2013; 110:14753-8.
38. Chang HW, Lin YW, Ho HM, et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and proinflammatory cytokines in human SCARB2-transgenic mice. PLoS One 2013; 8:269858.
39. Lee BY, Wateska A, Bailey RR, Tai JHY, Bacon KM, Smith KJ. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine 2010; 28:7731-6.
40. Chen CW, Lee YP,Wang YF, Yu CK. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 2011; 29:2772-6.